title: Central serous chorioretinopathy after renal transplantation.
abstract: OBJECTIVE
  To describe the demographic and clinical characteristics of central serous chorioretinopathy (CSC) after renal transplantation (RT).
  
  
  METHODS
  A retrospective medical chart review was performed on 451 among 2,980 patients, who underwent RT and visited vitreoretinal clinic at Yonsei Medical Center from 1979 to 2009. Correlation between daily corticosteroid dosage and remission time and factors relating to final visual acuity of <20/40 were studied.
  
  
  RESULTS
  Twenty-eight patients (39 eyes) developed CSC at a median of 63 months after RT (range, 2 months to 20 years), and 18 (64%) patients were men. Accordingly, the prevalence of CSC after RT was estimated to be between 1% and 6%. All patients received a combination of corticosteroid and at least one other immunosuppressant agent at presentation. Reducing the daily corticosteroid dosage by 25% to 50% in CSC with classic pattern resulted in twice as faster remission (2 months) compared with the maintained dosage group (P = 0.025). Central serous chorioretinopathy recurrence (P = 0.002), intrinsic renal disease as cause of RT (P = 0.003), severe CSC variant (P = 0.009), and presenting visual acuity <20/40 (P = 0.009) predicted a final visual acuity <20/40.
  
  
  CONCLUSIONS
  Central serous chorioretinopathy develops relatively often after RT and varies in presentation and severity. The cause of CSC after RT appears to be multifactorial and closely related to corticosteroid.
authors.affiliation: Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Christopher Seungkyu
authors.initials: CS
authors.lastname: Lee
authors.forename: Eui Chun
authors.initials: EC
authors.lastname: Kang
authors.forename: Kyu Sung
authors.initials: KS
authors.lastname: Lee
authors.forename: Seok Ho
authors.initials: SH
authors.lastname: Byeon
authors.forename: Hyoung Jun
authors.initials: HJ
authors.lastname: Koh
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Lee
mesh_terms: D000328:Adult; D056833:Central Serous Chorioretinopathy / Q000139:chemically induced* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011282:Pregnenediones / Q000008:administration & dosage; D012189:Retrospective Studies; D013997:Time Factors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011282:Pregnenediones; D011239:Prednisolone; C021988:deflazacort